MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2025 International Congress
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search

Articles tagged "Botulinum toxin: Clinical applications: dystonia"

  • 2022 International Congress

    Impact of botulinum toxin treatment on gait in focal dystonia

    J. Cuinat, B. Debu, P. Pelissier, A. Castrioto, S. Meoni, S. Potel, V. Fraix, E. Moro (Grenoble, France)

    Objective: To study the effects of botulinum neurotoxin (BTX) treatment on gait characteristics in patients with blepharospasm and cervical dystonia. Background: The impact of focal…
  • 2022 International Congress

    Changes in botulinum toxin dosing in cervical dystonia over 7 years

    S. Rafee, M. Hutchinson (Dublin, Ireland)

    Objective: To assess changes in botulinum toxin dosing over the course of illness of cervical dystonia. Background: Muscle specific botulinum toxin injections remains the main…
  • 2022 International Congress

    Use of bupivacaine in the evaluation of acute secondary cervical dystonia (CD)

    JR. Chai, S. Bansal, C. Li, M. Jog (London, Canada)

    Objective: To highlight the potential use of bupivacaine/analgesics in assessing cervical dystonia, where disabling local pain can be a confounder and limits clinical examination. Background:…
  • 2022 International Congress

    Botulinum Toxin Therapy for Medication and DBS Refractory Foot Dystonia of Parkinsonism

    E. Zinoviev, M. Ganapathy, M. Siddiqui (Winston-Salem, USA)

    Objective: To determine efficacy and safety of BTX therapy in patients with medically refractory foot dystonia secondary to Parkinson’s disease (PD) or atypical Parkinsonism (AP)…
  • 2022 International Congress

    Application of Goal Attainment Scale as a patient-centered assessment for cervical dystonia

    P. Wongwan, P. Panyakaew, R. Bhidayasiri (Bangkok, Thailand)

    Objective: To explore the goal attainment scale (GAS) by interviewing the three most disturbing problems and changes after Botulinum toxin A injection in cervical dystonia…
  • 2022 International Congress

    Oropharyngeal Dysphagia Before and After Botulinum Toxin Injection in Cervical Dystonia

    A. Silbergleit, L. Schultz, K. Isabell, J. Turnbull, E. Boettcher, R. Konnai, C. Sidiropoulos, N. Patel (West Bloomfield, USA)

    Objective: 1.To determine if Botulinum toxin (BoNT) injection improves oropharyngeal swallowing in individuals with cervical dystonia (CD) as determined by objective data from videofluorographic swallowing studies…
  • 2022 International Congress

    PHENOTYPIC DESCRIPTION OF TWO UNREPORTED FAMILIES WITH ANO3 DYSTONIA

    A. Trinchillo, G. de Joanna, M. Esposito (Naples, Italy)

    Objective: This is the phenotypic description of two families affected by hereditary dystonia associated to gene ANO3 mutation (DYT24), one with a heterozygous verisimilarly pathogenic…
  • 2022 International Congress

    Characterization of routine botulinum toxin (BoNT) therapy and patient population in cervical dystonia

    B. Waeschle, H. Stark, P. Albrecht (Düsseldorf, Germany)

    Objective: We conducted a survey to characterize real-world treatment of CD patients with focus on treatment duration, clinical parameters and awareness of clinical resistance as…
  • 2022 International Congress

    Does needle size matter in botulinum toxin injection? A crossover randomised controlled trial of microneedle in patients with hemifacial spasm

    S. Maytharakcheep, R. Bhidayasiri, O. Phokaewvarangkul (bangkok, Thailand)

    Objective: The aim of this study was to compare the severity of  pain and bruises between a microneedle (34-G) and standard needle (30-G) in patients…
  • MDS Virtual Congress 2021

    A Phase 3 Trial Evaluating the Efficacy, Duration of Effect, and Safety of DaxibotulinumtoxinA for Injection in the Treatment of Cervical Dystonia

    J. Jankovic, C. Comella, R. Hauser, A. Patel, T. Gross, R. Rubio, D. Vitarella (Houston, USA)

    Objective: To evaluate the efficacy and safety of two doses of DaxibotulinumtoxinA for Injection (DAXI) vs placebo for treatment of cervical dystonia (CD). Background: DAXI…
  • « Previous Page
  • 1
  • …
  • 6
  • 7
  • 8
  • 9
  • 10
  • …
  • 21
  • Next Page »

Most Viewed Abstracts

  • This Month
  • All Time
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • #24970 (not found)
  • Life expectancy with and without Parkinson’s disease in the general population
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • An atypical and interesting feature of Parkinson´s disease
  • Effect of marijuana on Essential Tremor: A case report
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Estimation of the 2020 Global Population of Parkinson’s Disease (PD)
  • Patients with Essential Tremor Live Longer than their Relatives
  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2026 International Parkinson and Movement Disorder Society. All Rights Reserved.
Wiley